
## Erminia Massarelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1340414/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related Cancer. JAMA Oncology, 2019, 5, 67.	3.4	344
2	Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. , 2018, 6, 46.		135
3	FAK-targeted and combination therapies for the treatment of cancer: an overview of phase I and II clinical trials. Expert Opinion on Investigational Drugs, 2020, 29, 399-409.	1.9	59
4	Immune Checkpoint Inhibitor–Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases. Oncologist, 2021, 26, 1052-1061.	1.9	50
5	Myeloid cell–targeted STAT3 inhibition sensitizes head and neck cancers to radiotherapy and T cell–mediated immunity. Journal of Clinical Investigation, 2021, 131, .	3.9	41
6	ISA101 and nivolumab for HPV-16 <sup>+</sup> cancer: updated clinical efficacy and immune correlates of response. , 2022, 10, e004232.		38
7	Checkpoint inhibitors in lung cancer: latest developments and clinical potential. Therapeutic Advances in Medical Oncology, 2016, 8, 460-473.	1.4	30
8	Role of immunotherapy and co-mutations on KRAS-mutant non- small cell lung cancer survival. Journal of Thoracic Disease, 2020, 12, 5086-5095.	0.6	29
9	A Non-genetic Mechanism Involving the Integrin β4/Paxillin Axis Contributes to Chemoresistance in Lung Cancer. IScience, 2020, 23, 101496.	1.9	27
10	Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure. Cancers, 2020, 12, 3851.	1.7	27
11	Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio. Lung Cancer, 2019, 133, 136-143.	0.9	21
12	The Effects of Time to Treatment Initiation for Patients With Non–small-cell Lung Cancer in the United States. Clinical Lung Cancer, 2021, 22, e84-e97.	1.1	19
13	Combined modality radiation therapy promotes tolerogenic myeloid cell populations and STAT3-related gene expression in head and neck cancer patients. Oncotarget, 2018, 9, 11279-11290.	0.8	19
14	Factors predicting for patient refusal of head and neck cancer therapy. Head and Neck, 2020, 42, 33-42.	0.9	17
15	Dynamic Phenotypic Switching and Group Behavior Help Non-Small Cell Lung Cancer Cells Evade Chemotherapy. Biomolecules, 2022, 12, 8.	1.8	13
16	Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer. Journal of Clinical Medicine, 2022, 11, 1429.	1.0	12
17	Postoperative radiation performed at the same surgical facility associated with improved overall survival in oral cavity squamous cell carcinoma. Head and Neck, 2019, 41, 2299-2308.	0.9	9
18	Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients. Cancers, 2021, 13, 2776.	1.7	9

Erminia Massarelli

#	Article	IF	CITATIONS
19	Comparing outcomes of concurrent chemotherapy regimens in patients 65 years old or older with locally advanced oropharyngeal carcinoma. Cancer, 2018, 124, 4322-4331.	2.0	8
20	Early mortality of stage IV non-small cell lung cancer in the United States. Acta Oncológica, 2019, 58, 1095-1101.	0.8	8
21	Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors. Lung Cancer, 2020, 146, 174-181.	0.9	8
22	Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer. JCO Oncology Practice, 2021, 17, e257-e265.	1.4	8
23	The Association between Polluted Neighborhoods and <i>TP53</i> -Mutated Non–Small Cell Lung Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1498-1505.	1.1	8
24	INDUCE-1: Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5-FU chemotherapy (5-FU/plat), with or without pembrolizumab (PE), for the treatment of advanced solid tumors Journal of Clinical Oncology, 2020, 38, 6544-6544.	0.8	8
25	Postoperative Radiation Therapy Should Be Used for Completely Resected Stage III-N2 NSCLC in Select Patients. Journal of Thoracic Oncology, 2022, 17, 194-196.	0.5	8
26	Biomarkers in immunotherapy: literature review and future directions. Journal of Thoracic Disease, 2020, 12, 5119-5127.	0.6	7
27	Precision medicine and actionable alterations in lung cancer: A single institution experience. PLoS ONE, 2020, 15, e0228188.	1.1	7
28	First-time in-human study of VMD-928, an oral allosteric TrkA selective inhibitor targeting TrkA protein overexpression, in patients with solid tumors or lymphoma Journal of Clinical Oncology, 2021, 39, 3081-3081.	0.8	6
29	Perspectives in Head and Neck Medical Oncology. Cancer Treatment and Research, 2018, 174, 163-185.	0.2	5
30	Immunotherapy in Non-Small Cell Lung Cancer Patients with Brain Metastases: Clinical Challenges and Future Directions. Cancers, 2021, 13, 3407.	1.7	4
31	Disparate outcomes in nonsmall cell lung cancer by immigration status. Cancer Medicine, 2021, 10, 2660-2667.	1.3	3
32	Prolonged response to checkpoint inhibitor therapy in two metastatic mucoepidermoid salivary gland carcinoma cases: a research report Cold Spring Harbor Molecular Case Studies, 2022, 8, .	0.7	3
33	Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors. Cancers, 2021, 13, 2653.	1.7	2
34	LIBRETTO-001 cohort 7: A single-arm, phase 2 study of neoadjuvant selpercatinib in patients with resectable stage IB-IIIA <i>RET</i> fusion-positive NSCLC Journal of Clinical Oncology, 2022, 40, TPS8594-TPS8594.	0.8	2
35	An Analysis and Comparison of Survival and Functional Outcomes in Oropharyngeal Squamous Cell Carcinoma Patients Treated with Concurrent Chemoradiation Therapy within City of Hope Cancer Center Sites. Journal of Clinical Medicine, 2020, 9, 3083.	1.0	1
36	Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations. Future Science OA, 2021, 7, FSO662.	0.9	1

ERMINIA MASSARELLI

#	Article	IF	CITATIONS
37	Factors predictive of 90â€day mortality after surgical resection for oral cavity cancer: Development of a recursive partitioning analysis for risk stratification. Head and Neck, 2021, 43, 2731-2739.	0.9	1
38	Narrative review of immunotherapy and radiation therapy in elderly patients. Translational Cancer Research, 2021, 10, 2620-2631.	0.4	1
39	KITE-439: A phase I study of HPV16 E7 T cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers Journal of Clinical Oncology, 2020, 38, TPS3149-TPS3149.	0.8	1
40	Nasopharyngeal Cancer: Is the Addition of Chemotherapy to Radiotherapy Worthwhile in an Era of Value-Based Care?. JCO Oncology Practice, 2020, 16, 711-712.	1.4	0
41	Alterations in STK11 to limit response to immune checkpoint inhibitors in lung cancer Journal of Clinical Oncology, 2020, 38, e21503-e21503.	0.8	0
42	Evaluation of immune-related adverse events in patients treated with sequential immunotherapy and tyrosine kinase inhibitor treatment in non-small cell lung cancer Journal of Clinical Oncology, 2020, 38, e21562-e21562.	0.8	0
43	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0
44	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0
45	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0
46	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0